Clinical trials: Stem Cell Transplant Complications, open to volunteers
Neuroblastoma, Rhabdomyosarcoma
Alpha/Beta T and B Cell Depletion With Zoledronic Acid for Solid Tumors
Hematopoietic stem cell transplantation can cure patients with blood cancer and other underlying diseases. αβ-T cell and B cell depletion has been introduced to decrease GVHD and PTLD and has demonstrated effectiveness for…
- Conditions
- Neuroblastoma, Rhabdomyosarcoma, Synovial Sarcoma, Peripheral Nerve Sheath Tumors
- Trial name
- NCT06625190
- Testing
- Miltenyi CliniMACS Prodigy ® system, Zoledronic acid
- Where
- United States
- Volunteers
- 27 people
- Sponsor
- University of Florida
Critical Illness, Ventilated Patients
Critical Illness After Hematopoietic Cell Transplantation
This is a prospective, multicenter observational trial for patients who develop critical illness after hematopoietic cell transplantation.
- Conditions
- Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
- Trial name
- CARE-HCT (NCT07328724)
- Where
- 6 sites in China
- Volunteers
- 4,000 people
- Sponsor
- Peking University People's Hospital
Stem Cell Transplant Complications, Acute Graft Versus Host Disease
Study on the Serum Metabolic Markers and Early Complications After Allo-HSCT： Cohort Study
This study aims to establish a cohort of 500 patients with hematological disease who undergoing allogeneic hematopoietic stem cell transplantation in the northwest region.
- Conditions
- Stem Cell Transplant Complications, Acute Graft Versus Host Disease, Acute Kidney Injury, Major Adverse Cardiac Events
- Trial name
- NCT06386445
- Testing
- Serum metabolomics sequencing
- Volunteers
- 500 people
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Allogeneic HSCT, Posttransplant Complications
Quantification of Peripheral Blood iNKTs After Allogeneic Stem Cell Transplantation
The transplantation of allogeneic haematopoietic stem cells (HSCs) can lead to serious complications after transplantation, such as graft-versus-host disease (GvHD), infections and relapse due to immunosuppression.
- Conditions
- Allogeneic HSCT, Posttransplant Complications, GvHD, Relapse
- Trial name
- QiNKT-HSCT (NCT07570407)
- Testing
- blood draw
- Where
- Czechia
- Volunteers
- 75 people
- Sponsor
- University Hospital Pilsen
Liver Transplant; Complications, Liver Diseases
Adipose-Derived Mesenchymal Stem Cell for Preventing Biliary Complications
The purpose of this study is to assess the safety of autologous Adipose-Derived Mesenchymal Stem Cell for use in End-Stage Liver Disease patients undergoing the creation of a duct-to-duct anastomosis during Living Donor Liver…
- Trial name
- NCT06649864
- Testing
- Autologous adipose derived mesenchymal stromal cells (AMSC)
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Mayo Clinic
Haemoglobin Barts Hydrops
In-utero Hematopoietic Stem Cell Transplantation for the Treatment of Fetuses With Bart's Hydrops Fetalis Syndrome
This is a prospective observational pilot study on pregnant women who are diagnosed to have Bart's hydrops fetalis syndrome (BHFS) affected fetuses and opt for continuation of pregnancy will be invited to consider undergoing…
- Trial name
- NCT05797272
- Testing
- in-utero HSCT
- Where
- Hong Kong
- Volunteers
- 10 people
- Sponsor
- Chinese University of Hong Kong
Cardiotoxicity, DPP3
Cardiovascular Complications in Patients Undergoing Allogeneic Hematopoietic Stem Cell Transplantation.
Allogeneic hematopoietic stem cell transplantation (HSCT) represents a major therapeutic strategy for malignant hematologic diseases, with the number of procedures steadily increasing in France each year.
- Conditions
- Cardiotoxicity, DPP3, HSCT, Allogeneic Hematopoietic Stem Cell Transplantation
- Trial name
- ALLOCARDIOTOX (NCT07157670)
- Where
- France
- Volunteers
- 400 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
AdV Infection, EBV Infection
Multivirus-specific T-cell Transfer Post SCT vs AdV, CMV and EBV Infections
Haematopoietic stem cell transplantation (HSCT) can expose patients to a transient but marked immunosuppression, during which viral infections are an important cause of morbidity and mortality.
- Conditions
- AdV Infection, EBV Infection, CMV Infection, Stem Cell Transplant Complications
- Trial name
- TRACE (NCT04832607)
- Testing
- Multivirus (CMV, EBV, AdV)-specific T cells
- Where
- 33 sites in Belgium, France and 4 more
- Volunteers
- 149 people
- Sponsor
- Tobias Feuchtinger
Chronic Disease, Immunocompromised
Integrating Vaccination Into Hospital Care Pathways for Vulnerable Patients
AMBU-VAX is a prospective, single-center observational study designed to develop and implement an organizational model for delivering recommended vaccinations within a hospital setting.
- Conditions
- Chronic Disease, Immunocompromised, HIV Infection, Chronic Kidney Disease
- Trial name
- AMBU-VAX (NCT07391046)
- Testing
- Hospital-Based Vaccination Pathway
- Volunteers
- 1,500 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
GVHD, Acute, Stem Cell Transplant Complications
Novel Therapies for Severe Acute GVHD (Graft-versus-host Disease)
The purpose of this study is to determine the efficacy and safety of combined Ruxolitinib With Corticosteroids as First Line Therapy for the severe acute GVHD (graft-versus-host disease )
- Trial name
- GVHD (NCT07509749)
- Testing
- Ruxolitinib and Methylprednisolone, Methylprednisolone
- Where
- China
- Volunteers
- 54 people
- Sponsor
- Daihong Liu
Relapsed Adult AML, Stem Cell Transplant Complications
Menin-Inhibitor Targeted Maintenance in AML
Revumenib is a first in class oral menin inhibitor that targets a central oncogenic dependency shared across KMT2Ar, NPM1m, and NUP98r AML.
- Conditions
- Relapsed Adult AML, Stem Cell Transplant Complications, Acute Myeloid Leukemia, Transplant-Related Hematologic Malignancy
- Trial name
- NCT07563010
- Testing
- Revumenib
- Volunteers
- 146 people
- Sponsor
- Center for International Blood and Marrow Transplant Research
Kidney Failure, Chronic, Kidney Transplantation
Immunological Reset to Enable Access to Hla-compatible Kidney Transplantation in Highly Sensitized Patients (RESET)
The purpose of this clinical trial is to evaluate whether a temporary reprogramming of the immune system can help highly sensitized (hyperimmunized) patients with end-stage kidney disease safely receive a compatible kidney…
- Conditions
- Kidney Failure, Chronic, Kidney Transplantation, Alloimmunization, HLA Sensitization
- Trial name
- HIPER-RESET (NCT07607197)
- Testing
- Autologous Hematopoietic Stem Cell Transplantation
- Where
- Spain
- Volunteers
- 10 people
- Sponsor
- Hospital Universitari Vall d'Hebron Research Institute
Graft Versus Host Disease in Eye, Ocular Complications
Ocular Complications From Cancer Therapy - Patient Registry and Biobank
The purpose of this study is to collect data on patients seen at University of Maryland after undergoing cancer therapy. Previous medications, ocular history, medical history, clinical evaluations, surgical procedures and…
- Conditions
- Graft Versus Host Disease in Eye, Ocular Complications, Inflammatory Dry Eye Disease
- Trial name
- NCT06874283
- Testing
- Eye exam
- Where
- United States
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- University of Maryland, Baltimore
Graft Failure, Stem Cell Transplant Complications
Second Haplo-transplantation for Graft Failure
Graft failure is a fatal complication following allogeneic stem cell transplantation where a second transplantation is usually required for salvage.
- Trial name
- NCT06512519
- Testing
- second allogeneic stem cell transplantation
- Where
- China
- Volunteers
- 34 people
- Sponsor
- Peking University People's Hospital
End Stage Kidney Disease, Immunological Tolerance
Delayed Immunological Tolerance in Patients With Well-functioning Pre-existing HLA-matched Kidney Transplants
The study seeks to determine if patients with a pre-existing, well-functioning kidney transplant from a HLA-identical living donor can be withdrawn from immunosuppressive medications without compromising allograft function…
- Conditions
- End Stage Kidney Disease, Immunological Tolerance, Kidney Transplant Failure and Rejection, Chronic Kidney Diseases
- Trial name
- NCT05525507
- Testing
- Conditioning and Stem cell infusion
- Where
- United States
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- University of California, Los Angeles
Chronic Kidney Diseases, Kidney Transplant
Safety and Tolerability of Vertebral Bone Marrow-derived Mesenchymal Stem Cells (BM-MSC) in Real World Scenarios of Patients With Chronic Kidney Disease (CKD)
The purpose of this protocol is to treat an intermediate-sized population with chronic kidney disease (CKD) including kidney transplant recipients. The protocol uses allogeneic bone marrow-derived mesenchymal stem cells (MSCs).
- Trial name
- NCT06752577
- Testing
- Allogeneic, vertebral bone marrow-derived mesenchymal stem cells (MSC)
- Where
- United States
- Volunteers
- 75 people
- Sponsor
- Mayo Clinic
Stem Cell Transplant Complications, Sleep Disturbance
Developing Restful Environments and Management Strategies for Pediatric Stem Cell Transplant Patients
Pediatric patients undergoing stem cell transplant (SCT) are hospitalized for extended periods and are at high risk for sleep disturbances.
- Trial name
- DREAMS (NCT06468618)
- Testing
- DREAMS Program Video and Care Kit
- Where
- 2 sites in United States
- Volunteers
- 10 people
- Sponsor
- Dana-Farber Cancer Institute
SIOD, Cystinosis
Early Trial of Allogeneic Hematopoietic Stem Cell Transplantation for Patients Who Will Receive a Kidney Transplant From the Same Donor
This is a single center, non-randomized, non-controlled open-label phase 1b/2a trial of performing sequential αβdepleted-HSCT and KT in patients requiring KT to prevent kidney rejection post-KT, in the absence of any post-KT…
- Conditions
- SIOD, Cystinosis, FSGS, SLE Nephritis
- Trial name
- NCT05508009
- Testing
- Cyclophosphamide 1200 mg/Kg, Fludarabine, Cyclophosphamide 100 mg/Kg
- Where
- United States
- Volunteers
- 12 people
- Sponsor
- Alice Bertaina
Transplant Complication
Oral Pooled Fecal Microbiotherapy to Prevent Allogeneic Hematopoietic Cell Transplantation Complications (PHOEBUS Trial)
This randomized, placebo-controlled phase IIb study (PHOEBUS trial) aims to evaluate the activity of fecal microbiotherapy MaaT033 to improve survival through the prevention of transplant-related complications in eligible alloHCT…
- Trial name
- NCT05762211
- Testing
- Pooled allogeneic fecal microbiotherapy
- Where
- 54 sites in Belgium, France and 4 more
- Volunteers
- 387 people
- Sponsor
- MaaT Pharma
Multiple Myeloma, Complication
PASCA-MM Study. Impact of the PASCA (PArcours de Santé au Cours du CAncer) Program on Complications Associated With Multiple Myeloma and/or Its Treatments in the Context of a First Hematopoietic Stem Cell Autograft, in Adults Aged 18 to 70.
This is a prospective, multicentre, phase III, randomised, controlled intervention study. Two groups of patients with equal numbers will be studied and each patient will be allocated to one of the two groups described below by…
- Trial name
- PASCA -MM (NCT05947136)
- Testing
- Interpretation of the results from the detection visit, Explaining detection results and referrals to the patient, Early medical care through the network
- Where
- 6 sites in France
- Volunteers
- 204 people
- Sponsor
- Centre Leon Berard